<DOC>
	<DOCNO>NCT00908089</DOCNO>
	<brief_summary>The FIN-RACo trial investigator initiate multicenter ( n=15 center Finland ) prospective study treatment patient early rheumatoid arthritis ( RA ) combination therapy disease modify antirheumatic drug start methotrexate , sulphasalazine , hydroxychloroquine prednisolone ( COMBI ) . During first 6 month , patient randomize treatment infliximab/placebo add combination treatment . The study prospective 5 year , extension 10 year . The target induce remission treatment arm . To reach target , investigator use frequent change dose anti-rheumatic drug use intra-articular glucocorticoid injection . The primary endpoint proportion patient remission 2 5 year treatment arm .</brief_summary>
	<brief_title>TNF-blocking Therapy Combination With Disease-modifying Antirheumatic Drugs Early Rheumatoid Arthritis</brief_title>
	<detailed_description>We want study , whether early treatment infliximab 6 month start parallel combination therapy methotrexate , sulphasalazine , hydroxychloroquine prednisolone ( COMBI ) induce quick remission patient early RA , remission sustain 6 month patient continue COMBI treatment diminish risk progression erosive change patient early RA , reduce cost 2 treatment arm respect cost due disease . 100 patient early RA include study . The patient randomise COMBI + placebo COMBI +infliximab . All patient treat openly COMBI , start combination methotrexate , sulfasalazine , hydroxychloroquine prednisolone . In addition , patient randomize ) infliximab b ) similar placebo . The COMBI treatment continue 2 year , infliximab/placebo give first 6 month . After 2 year , patient remission , prednisolone gradually taper . If patient still remission , conventional DMARDs sequentially taper . If remission lose , last DMARD reinstituted . If patient remission COMBI , 26 week , treatment free , include institution biological drug . The patient evaluate clinically week 0 , 4 , 6 , 10 , 14 , 18 , 22 26 ( day infusion , prior infusion ) month 8 , 10 , 12 , 15 , 18 , 21 , 24 annually thereafter till 10 year . If patient adverse event due individual drug COMBI , treatment substitute another DMARD.The disease activity measure accord ACR core set disease activity . Radiology hand ( PA projection ) foot ( PA projection ) baseline 1 , 2 , 3 , 4 , 5 , 7 10 year . We also record adverse event , sick leaf , loss income , cost , work disability .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Diagnosis RA fulfil ACR classification criterion RA Patients within age group 1860 year Patients permanently work disabled retired Duration symptom &lt; 12 month , receive DMARD previously Patients active disease ( see ) Criteria active disease entry : &gt; 6 swollen joint ( 66 joint count ) &gt; 6 tender joint ( 68 joint count ) duration early morning stiffness &gt; 45 min and/or ESR &gt; 30 mm/h and/or CRP &gt; 20 mg/l Previous treatment DMARDs Previous treatment oral glucocorticoid previous 6 month Less 30 day previous intraarticular injection corticosteroid Allergy sulphonamides Allergy acetylsalicylic acid Allergy methotrexate Allergy antimalarial Previous treatment biologicals Serum creatinine value &gt; upper limit normal ( registered 2 different blood sample ) Serum transaminase level &gt; 2x upper limit normal ( registered 2 different sample ) Known/previous malignancy exclude basalioma situ cervical cancer &gt; 5 year previously Cardiac failure ( NYHA IIIIV ) Previous history tuberculosis and/or exposition tuberculosis and/or typical change previous/active tuberculosis chest radiology Active infection Pregnancy Leukopenia ( WBC &lt; 4 x 109/l ) Thrombocytopenia ( platelet &lt; 100 x 109/l ) Active peptic ulcer Type I type II diabetes poor control Heavy use alcohol Fertile woman practise contraception planning pregnancy Male patient wish child therapy Other autoimmune rheumatic disease Other chronic disease judge physician could influence patient 's compliance intervene study course Patient cooperative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>methotrexate</keyword>
	<keyword>sulfasalazine</keyword>
	<keyword>hydroxychloroquine</keyword>
	<keyword>infliximab</keyword>
</DOC>